Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.71 |
| ▸ | HTR3A | P46098 | 4/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | ATF4 | P18848 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1376869 | 0.86 | HRH3 (0.69) | HRH3HTR3ACHRM2SLC6A2ADRA1A | |
| SCHEMBL10259154 | 0.85 | HRH3 (0.73) | HRH3HTR3ACHRM2SLC6A2ADRA1A | |
| SCHEMBL1375052 | 0.83 | HRH3 (1.00) | HRH3HTR3ACHRM2SLC6A2ADRA1A | |
| SCHEMBL1375049 | 0.83 | HRH3 (1.00) | HRH3HTR3ACHRM2SLC6A2ADRA1A | |
| SCHEMBL1373074 | 0.82 | HRH3 (1.00) | HRH3HTR3ACHRM2SLC6A2ADRA1A | |
| SCHEMBL1373297 | 0.81 | HRH3 (1.00) | HRH3HTR3ACHRM2SLC6A2ADRA1A | |
| SCHEMBL10259128 | 0.78 | HRH3 (0.69) | HRH3HTR3ACHRM2SLC6A2ADRA1A | |
| SCHEMBL1374866 | 0.77 | HRH3 (0.69) | HRH3HTR3ACHRM2SLC6A2ADRA1A | |
| SCHEMBL12699737 | 0.74 | HRH3 (0.71) | HRH3HTR3A | |
| SCHEMBL23297265 | 0.73 | LMNA (0.59) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247414-B2 | Pyridizinone derivatives and the use thereof as H3 inhibitors | CEPHALON, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8207168-B2 | Pyridazinone derivatives | CEPHALON, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110288075-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100280007-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100273779-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20080027041-A1 | Pyridizinone derivatives | CEPHALON, INC. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027041-A1 | Pyridizinone derivatives | H1-5, H1-3, H1-4 | HRH3 4/4885HTR3A 347/4885CHRM2 357/4885 |
| US-20100280007-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | HRH3 1/4885HTR3A 15/4885CHRM2 74/4885 |
| US-20110288075-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | HRH3 1/4885HTR3A 16/4885CHRM2 76/4885 |
| US-20100273779-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | HRH3 1/4885HTR3A 15/4885CHRM2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.